Box News

Both psoriasis and eczema involve the immune system, but they do so in different ways and for different reasons. Psoriasis is best thought of as an immune-driven, hyperproliferative disease of the skin: specific immune cells (notably Th17-type T cells) and the cytokines they produce — especially the IL-23 → IL-17 pathway — stimulate skin cells (keratinocytes) to divide and turn over far faster than normal. That overactive signal loop produces the well-defined, thick, scaly plaques and also explains why many modern psoriasis treatments target those cytokines. (PubMed Central)

Atopic eczema (atopic dermatitis) is also immune-mediated, but the immune problem usually starts because the skin’s outer barrier is weak. Genetic differences (for example, loss-of-function changes in the filaggrin gene) and other factors make the skin dry and leaky so allergens, microbes, and irritants penetrate more easily. The immune response that follows is skewed toward a type-2 (Th2) pattern — with cytokines such as IL-4 and IL-13 — which drives itch, inflammation, and allergic features (for example raised IgE in many patients). Repairing the barrier and blocking the Th2 signals are therefore central to eczema care. (The Lancet)

Those two pictures — a primarily Th17/IL-23 driven, keratinocyte-hyperproliferative process in psoriasis, and a barrier-failure plus Th2-dominated allergic inflammation in eczema — explain much of their clinical difference: psoriasis lesions tend to be sharply bordered and scaly, while eczema is usually very itchy, more likely to weep or crack, and often shows a history of allergies. At the same time, the immune system elements are not totally separate: both diseases can activate overlapping pathways (for example Th22 and sometimes Th1), some patients show mixed immune signatures, and population or age differences can blur the classic patterns. That overlap helps explain why a few treatments and some research findings apply to both conditions, even though their dominant drivers differ. (Frontiers)

The practical consequence is that diagnosis and treatment focus on the dominant mechanism for each person. In psoriasis the clinical strategy often emphasizes reducing the pathological T-cell and cytokine signaling that speeds skin-cell growth (for example biologics that block TNF, IL-23 or IL-17), while in atopic eczema the emphasis is on restoring the barrier (moisturizers, emollients, avoiding triggers) and calming Th2 inflammation — for which therapies such as dupilumab (an IL-4/IL-13 receptor blocker) have been developed. Because the immune patterns differ, a medication that works very well for one disease may be ineffective or less helpful for the other. (ScienceDirect)

In short: both psoriasis and eczema are disorders in which the immune system plays a central role, but psoriasis behaves more like an autoimmune, Th17-driven attack that accelerates skin growth, whereas atopic eczema begins largely with barrier failure and a Th2/allergic immune response that promotes intense itch and sensitivity. Recognizing those shared and distinct mechanisms is what guides diagnosis, avoidance strategies, and the choice of targeted therapies. (PubMed Central)

(Source : ChatGPT)

Psoriasis :

Psoriasis happens when the body’s immune system sends the wrong signals and makes skin cells grow too fast. Instead of taking weeks for old skin to shed and new skin to form, the cycle speeds up to days, so dead skin piles up and makes the thick, scaly patches people see. Psoriasis is not contagious — you can’t catch it from someone else. (Mayo Clinic)

At the root of that problem are immune cells (especially a type called T cells) and chemical messengers they use, which cause inflammation in the skin. Scientists have identified specific immune pathways — commonly named IL-23 and IL-17 — that drive the inflammation and the too-rapid growth of skin cells. Those immune signals are a major focus of modern treatments. (Nature)

Genes matter too. People with a family history of psoriasis are more likely to get it, and researchers have found several genetic differences that increase risk. But genes don’t tell the whole story: having a risky gene doesn’t always mean you will get psoriasis. (Académie Américaine de Dermatologie)

Often, something in the environment or a specific event will trigger the first episode or a flare-up. Common triggers include throat infections (like strep), cuts or skin injuries, certain medicines, emotional stress, smoking, heavy alcohol use, and being overweight. Weather changes and other factors that irritate the skin or increase inflammation can also make psoriasis worse. Because psoriasis is the result of both a genetic tendency and outside triggers, what brings on a flare differs from person to person. (nhs.uk)

Put simply: psoriasis is a chronic condition caused by an overactive, misdirected immune response in people who are genetically prone to it, and it is often started or made worse by infections, skin injury, medicines, stress, or lifestyle factors. Treatments aim to calm the immune reaction and reduce inflammation, and many people find a combination of medical therapy and trigger-management helps control symptoms. (Mayo Clinic)

Eczema : 

Eczema (often called atopic dermatitis) happens because of two things working together: a weak outer skin barrier and an immune system that overreacts. When the skin barrier is not doing its job—either because of inherited differences in skin proteins or simply because the skin is very dry—water escapes and tiny gaps open that let allergens and irritants get in. That makes the skin sensitive, dry, and prone to cracking. (CBI)

One important piece of the skin-barrier problem is a protein called filaggrin. Some people are born with changes in the gene for filaggrin that make their skin barrier less effective. When the barrier is weakened in this way, ordinary things in the environment—dust, pollen, pet dander, or even some soaps—can sneak into the skin and set off trouble. Researchers have found that filaggrin problems are a major risk factor for atopic eczema. (jacionline.org)

The immune system is the other main part of the story. In people with eczema, the immune system reacts too strongly to those irritants and allergens. That reaction causes inflammation, which looks and feels like redness, swelling, and intense itching. The itch is important because scratching makes the skin even more damaged and lets germs in, which can lead to infections and more inflammation. (Mayo Clinic)

Outside factors often trigger the first flare or make existing eczema worse. Common triggers include harsh soaps and detergents, certain fabrics, dry or very hot weather, sweat, infections of the skin, stress, and sometimes foods or airborne allergies. Different people have different triggers, and what sparks one person’s flare might not affect someone else. Paying attention to personal triggers is a big part of managing the condition. (nhs.uk)

It’s also important to know that “eczema” is a general name for several kinds of skin inflammation. Atopic dermatitis (the kind linked to allergy, asthma, or hay fever) is the most common and follows the pattern above. Other types, like contact dermatitis, happen when the skin reacts directly to an irritant or an allergen it touches (for example, nickel in jewelry or a particular lotion). The causes and best ways to avoid them can be different. (Académie Américaine de Dermatologie)

In short, eczema comes from a mix of inherited skin-barrier weakness and an overactive immune response, with everyday irritants, infections, weather, and stress often acting as triggers. Because both the barrier and the immune system are involved, treatments focus on repairing and protecting the skin and calming inflammation, while also avoiding personal triggers. If you want, I can rewrite this as a patient handout or a very short explanation for a child. (jacionline.org)

(Source : ChatGPT 1 , 2 )

Mechanisms of Actions :

The immune response is a tightly regulated process where any imbalance in its strict regulation could lead to pathological conditions. The important role of ion channel stability in immune function is becoming more apparent. After immune activation, changes in the cells' microenvironment are integrated into a survival response by complex signal transduction mechanisms. Lipid nanopores forming stable ion channel conduction pathways in the plasma membrane of cells explain the conduction of ions into the cell from the extracellular space. It has been postulated that a direct effect of PEMF on phospholipids within the plasma membrane stimulates the production of second messengers, initiating multiple intracellular signal transduction pathways. PEMF can alter cell function by triggering the forced vibration of free ions on the surface of the plasma membrane, causing external oscillating field disruptions in the electrochemical balance of transmembrane proteins (ion channels).

The formation of a complex multicellular organism from a single cell is one of the most amazing processes of biology. Embryonic development is characterized by the careful regulation of cell behaviors such as cell proliferation, migration, differentiation, and tissue formation at the perfect time and place. These processes are dependent on the activities of genetics, signaling pathways, and information processing that coordinate cellular interactions leading to organogenesis. During human development, lineage-committed cells of the three embryonic germ layers migrate and proliferate in the form of endogenous ionic currents, giving rise to EFs. While endogenous EFs are present in all developing and regenerating animal tissues, their existence in inflammatory/immune modulation and tissue regeneration has been largely ignored. Ion flux is closely involved in differentiation control as stem cells migrate and proliferate in specific directions to form tissues and organs, each having their own signature characteristics to form specific cell and tissue types. Applying the PEMF would modulate mechanisms of action that play significant roles in action potential/voltage-gated ion regulation. The density of the musculoskeletal system versus the delicacy of the immune system shows two very different characteristics in human physiology; therefore, the targeted tissue would require different dosimetry.

The mechanisms through which PEMF exchanges information between cells, and how the conversion of this biochemical signaling is translated, have been researched for decades showing that the PEMF can permeate both the plasma and nuclear membranes of cells, thereby affecting a variety of cell functions and tissue types. For example, PEMF can induce depolarization in the cell membrane, followed by an increase or decrease of intracellular calcium (Ca2+). While Ca2+ release from voltage-gated Ca2+ channels (VGCCs) regulates immune responses to pathogens, inhibiting VGCCs in infected macrophages can reduce calcium influx, upregulating the expression of proinflammatory genes. As biophysicists point out, a very important factor for regulating cell homeostasis is the level of the resting potentials, generated on the cell membrane. VGCCs are activated by membrane depolarization in action potentials, and when regulated by physical stimuli, VGCCs play a pivotal role in MSC differentiation. Levin and colleagues have shown that human MSC differentiation is accompanied by progressive hyperpolarization of voltage-gated ion channels. Artificial depolarization keeps these cells in an undifferentiated state, whereas artificial hyperpolarization accelerates differentiation. Poor regenerative capacity of musculoskeletal tissue has been the focus of regenerative medicine for many years. VGCCs are a group of membrane proteins that are predominantly found in excitable cells, such as cardiomyocytes, muscle, neurons and glial cells. VGCCs are known for their involvement in electrical current generation but are also expressed in nonexcitable cells including osteoblasts and chondrocytes. VGCCs increase intracellular Ca2+ concentration, which leads to the initiation of different physical stimuli, such as electrical, electromagnetic/magnetic, and mechanical function in regenerative processes. The bioelectric properties of a cell are mainly defined by the cellular membrane potential that controls different cell functions, which depend on the particular cell type. Electrically charged membranes tightly regulate the concentration of ions such as electrically charged Ca2+, sodium (Na+), and/or potassium (K+), which MSCs use as potent signal mediators. Here is where the effects of PEMF in cells occur, triggered at the membrane level. Evidence shows that PEMF can act on Ca2+ concentrations, Ca2+-dependent pathways, as well as Na+ and K+ pathways. PEMF can affect action potentials and hyperpolarization to modulate endogenous electrical potentials in plants, animals, and humans. Multiple factors cause discrepancies in the outcomes of PEMF-exposed cells during the inflammatory response. These variations include frequency, intensity, time of exposure and waveform, as well as the biological sample. The goal is to find the optimal PEMF dosimetry for creating homeostasis of cytokine signaling, transcription factors, and ion-flux-driven action potentials.

(Source :  National Institutes of Health)

Viewed through the lens of ritual and shamanic practice, cannabis in ancient China was less a single pharmacological agent and more a culturally-embedded tool for mediating altered states of consciousness, communicating with spirits, and marking transitions such as death and healing. Archaeological, textual and comparative evidence together suggest that the plant’s psychoactive capacities were recognized and intentionally harnessed in a range of religious and ritual contexts.

The clearest archaeological signal comes from the Yanghai burials in the Turpan Basin (Xinjiang), where well-preserved caches of cannabis — including flowering tops and seeds — were placed with the dead roughly 2,500 years ago. The context of one richly furnished grave, interpreted by the excavators as that of a ritual specialist or shaman, and the predominance of female (flowering) material rather than fiber or seed, strongly imply ritual or psychoactive use rather than merely textile or dietary use. This find sits alongside chemical and residue work showing that smoking and inhalation of cannabis occurred in western China by the same period, consistent with ritual inhalation as a technique for inducing trance. (ScienceDirect)

Classical Chinese texts and later medical and ritual literature record a long familiarity with hemp (má, 麻) and its varied powers. Works in the materia medica tradition attributed to Shén Nóng discuss hemp’s therapeutic and tonic uses, while also preserving cautions about strong preparations producing “numbness” or altered perception. Those textual notes fit a cultural pattern in which different plant parts and formulations (seeds, flowers, infusions, smoke) were used for distinct ends: the seed as a food-medicine and the flowering tops in more potent, sometimes ecstatic, applications. (PMC)

The figure of the shaman — a routinized intermediary who enters nonordinary states to heal, divine or guide the community — provides a useful interpretive frame. Ethnographic and historical studies indicate that mobile pastoral groups and early steppe cultures across Eurasia commonly incorporated psychoactive plants into shamanic rituals, and that such practices spread with cultural contacts and exchanges. In northwestern China the archaeological pattern (repeated associations of cannabis with graves interpreted as ritual specialists) and the botanical emphasis on resinous flowering material support the reading that cannabis was used to induce or intensify trance states during divination, funerary rites, or healing ceremonies. (nomadit.co.uk)

Classical medical anecdotes — most famously the accounts surrounding the surgeon-physician Hua Tuo and the mysterious “mafeisan” (麻沸散, literally “cannabis-boiling powder”) — further illustrate how powerful herbal preparations could be conceived as producing profound stupefaction or insensibility useful for surgery and other interventions. Scholarship remains divided about the exact ingredients and historicity of some recipes, but the narratives underscore that concentrated preparations of narcotic plants occupied a recognized place in clinical and ritual repertoires. (Wikipédie)

Interpreting these data together requires caution. Texts preserve medical theory and moralizing frameworks (yin/yang, qi, humoral-like categories) rather than pharmacological descriptions, and archaeological association does not by itself prove ritual function — but where botanical, contextual and comparative evidence converge (flowering material in ritual graves; residue evidence for inhalation; ethnographic parallels), the most parsimonious reading is that cannabis was intentionally used to access nonordinary states for social, sacred and therapeutic ends. Over time, those ritualized practices were folded into broader medicinal uses, giving ancient Chinese culture a multifaceted relationship with hemp that ranged from everyday nourishment (seed) to the sacralized, mind-altering applications of the shaman’s toolkit.

For modern readers this history is informative in two ways. First, it highlights that human use of cannabis for trance and ritual is ancient and cross-cultural, rooted in specific material preparations and social roles rather than in a single abstract pharmacology. Second, it warns against simplifying ancient practice to a single modern compound (e.g., CBD): the plant was used whole, in varied preparations, and understood through frameworks quite different from contemporary biomedical categories. The archaeological and textual record thus offers a textured picture: one of practical experimentation, ritual expertise, and culturally situated knowledges that recognized and employed the plant’s capacity to alter perception and mediate encounters between human and spirit. (ScienceDirect)

Here are a few interesting historical quotes regarding the use of cannabis in ancient Chinese medicinal or shamanic contexts:

1. “The flowers when they burst (when the pollen is scattered) are called 麻蕡 [ma‑fen] … if one takes much one sees demons and throws oneself about like maniacs. But if one takes it over a long period of time one can communicate with the spirits and one’s body becomes light.” — from commentary on the Shennong Bencao Jing (traditional Chinese pharmacopeia) as cited by historians. (Wikipédia)

2. “Hemp‑seeds … are very little used in medicine, but the magician‑technicians say that if one consumes them with ginseng it will give one preternatural knowledge of events in the future.” — from Tao Hongjing’s Ming yi bie lu (5th–6th c. CE) as quoted in historical studies of Chinese hemp. (Rex Research)

3. “In ancient China … medicine had its origin in magic. Medicine men were practicing magicians.” — from modern commentary on shamanic/medical practices in ancient China, referring to the role of the wu and plant‑rituals. (eden-saga.com)

4. Chinese: 「欲呼鬼神，恒服麻蕡。」
   English: “If one wishes to summon ghosts and spirits, one should continually consume the flowering tops of hemp.” Wikipédia+2PubMed Central+2
   (Attributed to the Wu Zang Jing (五臟經) “Five Viscera Classic”, 6th c Chinese medical text.)

(Source : ChatGPT , 2 , 3 )

Viewed through the lens of ancient Chinese thought, cannabis was first recorded not as a single isolated chemical like cannabidiol (unknown to them) but as a multifaceted medicinal plant called má (麻, often written dàmá 大麻) whose parts — seed, flower, leaf and stem — had distinct uses and effects. The plant appears in the earliest Chinese materia medica traditionally attributed to the culture-hero Shén Nóng (the Shennong Bencao Jing), a work whose authorship and exact date are legendary but which preserves recipes and observations that were later central to Chinese medical practice. In that tradition the hemp seed (huo ma ren) was prized for gentle laxative and tonic effects, while flowers and other parts were used for wounds, pain and conditions described in the language of classical medicine; some sections explicitly warn that certain components could cause numbness or other strong effects. (Wikipédia)

Ancient Chinese practitioners did not explain cannabis effects in modern biochemical terms; they interpreted its actions through the conceptual framework of Traditional Chinese Medicine — balancing qi, harmonizing yin and yang, and restoring flow along the channels (meridians). Remedies were selected to correct specific patterns such as “wind,” “cold” or “stagnation,” and cannabis was simply one herb among many that could warm, move, moisten or calm depending on how it was prepared and combined. Practical observations — for example that some preparations produced numbness, reduced pain, or altered perception — were folded into these diagnostic categories rather than used to infer molecular mechanisms. (PMC)

The classical sources and later commentaries also record more dramatic medicinal uses that suggest awareness of the plant’s stronger, narcotic properties. Famous medical accounts attribute an anesthetic formula called máfèisǎn (麻沸散, often translated “cannabis-boiling powder”) to the surgeon Hua Tuo (c. 140–208 CE), who is said to have given patients a wine-based herbal tonic that produced deep insensibility for surgical procedures. Whether the precise recipe actually contained high-THC material cannot be proven from the texts alone, but the clinical description demonstrates that early Chinese medicine had empirical knowledge that cannabis could blunt sensation and alter consciousness when used in concentrated preparations. (PubMed)

Archaeology and later scholarship support a long and regionally varied relationship with hemp in China: fiber and seed uses go back millennia, while medicinal and ritual uses persisted in both folk and elite streams of practice. In religious or shamanic contexts, cannabis was sometimes associated with trance and altered states — a cultural niche entirely coherent with its recorded pharmacological effects even though ancients lacked any concept of individual cannabinoids. The medical texts’ mixture of therapeutic praise, practical dosages, and cautious warnings reflects a pragmatic tradition that emphasized preparation, indication and balance. (PMC)

From our modern vantage point we can say that what the ancient Chinese observed were the plant’s whole-plant effects — a complex blend of compounds producing digestive, dermatological, analgesic, laxative and in some formulas intoxicating effects — but they had no means to separate cannabidiol (CBD) from other constituents. CBD itself was not isolated until the 20th century (first identified by Roger Adams in 1940), and the later chemical and pharmacological work that defined CBD’s distinctive non-intoxicating profile postdates the entire classical era. Thus the ancient Chinese view remains best read as a careful, clinically oriented catalogue of what the hemp plant did in practice, interpreted through the medical theories and therapeutic aims of their time. (PubMed)

(Source : ChatGPT)

Cannabidiol’s history stretches from ancient folk medicine to contemporary, tightly regulated clinical trials. Cannabis was used medicinally in many cultures for millennia — it appears in classical Chinese pharmacopoeia attributed to Emperor Shén Nóng around 2700–2800 BCE and is recorded across Asia, the Middle East and India for pain, spasms and other ailments. (The University of Sydney)

In the modern Western medical era, an important early figure was the Irish physician William B. O’Shaughnessy, who in the late 1830s (published 1839) documented cannabis preparations for treating pain, spasms and cholera while working in Calcutta and helped introduce cannabis into Victorian medicine. (The Public Domain Review)

The chemical study of cannabis compounds began in the 20th century. In 1940 Roger Adams and colleagues isolated cannabidiol (CBD) from hemp oil (they reported it as a derivative), marking the first clear chemical isolation of CBD from the plant. Early mid-century work identified cannabinoids but left some structural questions unresolved. (American Chemical Society)

A decisive advance came in the 1960s with the Israeli chemist Raphael Mechoulam and collaborators: in 1963 Mechoulam and Shvo published the correct structure of cannabidiol, and in 1964 Mechoulam (with Yechiel Gaoni) elucidated the structure of Δ9-tetrahydrocannabinol (THC), the primary psychoactive constituent. These structural discoveries opened the door to systematic pharmacology and later to the discovery of endogenous cannabinoids (the body’s own “endocannabinoid” system). (PubMed)

From the 1970s onward, basic science and animal studies expanded rapidly, and by the 1990s researchers had identified endocannabinoids and cannabinoid receptors, providing a physiological framework that explained how plant cannabinoids like CBD could influence pain, seizure thresholds, mood and inflammation. This era set the stage for clinical research into specific therapeutic uses. (PMC)

The 2000s–2010s saw the first regulatory approvals for cannabis-derived medicines: nabiximols (Sativex®, a roughly 1:1 THC:CBD oromucosal spray) gained approvals in several countries for spasticity in multiple sclerosis in and after 2010, reflecting acceptance of standardized botanical extracts in some national formularies. Then, in a landmark for CBD specifically, the U.S. Food and Drug Administration approved Epidiolex® (a purified, plant-derived CBD oral solution) on 25 June 2018 for certain severe childhood epilepsies (Lennox–Gastaut and Dravet syndromes, later expanded), based on randomized controlled trials showing seizure reduction. Those regulatory steps mark CBD’s movement from isolated compound and experimental therapy into licensed medical products. (Therapeutic Goods Administration (TGA))

Since those approvals, research has broadened: clinical trials and observational studies have investigated CBD for pain, anxiety, sleep, inflammation and a range of neurological and psychiatric conditions, producing mixed but sometimes promising results. At the same time, a massive consumer market for unregulated CBD products emerged, creating regulatory and quality-control challenges that health agencies continue to address. The scientific arc therefore runs from ancient empirical use, through mid-20th-century chemical isolation and 1960s structural elucidation, to modern mechanistic science and the first regulatory endorsements of CBD-based medicines in the 2010s. (PMC)

(Source : ChatGPT)

To understand why CBD may help, it helps to know that the skin has its own endocannabinoid system — a network of receptors, enzymes, and signalling molecules that influence inflammation, immune responses, oil production, and how skin cells (keratinocytes) grow and differentiate. CBD interacts with parts of this system (and with other targets such as TRP channels and nuclear receptors) and produces several effects that are directly relevant to eczema and psoriasis. First, CBD has anti-inflammatory activity: in cells and animal models it lowers production of pro-inflammatory cytokines that drive redness, swelling and immune activation in these diseases. Second, CBD can reduce itch signals partly by acting on channels involved in sensory neurone signalling. Third, in psoriasis (which involves excessive keratinocyte proliferation and abnormal differentiation) CBD and related cannabinoids have been shown in lab studies to slow keratinocyte growth and help normalize their behaviour — which could reduce scaling and thickening. Finally, CBD has antioxidant properties and can support skin barrier function and hydration in some formulations, which helps with dryness and irritation. (The Lancet)

What the clinical studies actually show so far: meta-analyses and recent systematic reviews report that topical cannabinoids, including CBD-containing preparations, produce a modest but statistically significant reduction in pruritus (itch) and some symptom improvement in small trials, but results for broader skin-disease outcomes (clearance, long-term control) are inconsistent because studies use different products, doses, and endpoints. In plain terms: many people and some small studies report less itch and less inflammation when using topical CBD products, but we do not yet have many large, high-quality randomized controlled trials proving they reliably change the course of eczema or psoriasis. (Frontiers)

Safety and practical points. Topical CBD preparations are generally well tolerated in the short term, with irritation or allergic reactions being the most common local problems; however, the regulatory and quality landscape is messy. Non-prescription CBD creams can vary widely in CBD concentration, purity, and may contain undeclared THC or contaminants. Oral/systemic CBD (not usually necessary for topical skin problems) carries additional risks such as drug interactions and, at high doses, possible liver enzyme elevation — so it’s important to be cautious if you take other medications. Because formulations matter a lot for skin penetration and effect, and because manufacturers differ, it’s sensible to choose products from reputable companies that provide third-party lab testing, to patch-test a new product on a small area first, and to talk with your dermatologist before starting CBD if you have moderate–severe disease or are on systemic medications. Also remember that, as of now, CBD products (except prescription drugs like Epidiolex for seizure disorders) are not approved by major regulators specifically for eczema or psoriasis. (library.samhsa.gov)

In short: the biology behind CBD makes it a plausible and sometimes effective option for reducing inflammation and itch in eczema and psoriasis, especially when used topically; but evidence from large clinical trials is still limited, product quality varies, and medical oversight is recommended for anything beyond light, short-term symptom use. If you’re considering trying CBD for your skin, a practical approach is to discuss it with your clinician, pick a well-tested topical product, patch-test it first, and treat it as one part of a broader skin-care plan (emollients, trigger control, and prescribed therapies when needed). (PMC)

(Source : ChatGPT)

EGCG (pronounced "E-G-C-G") stands for epigallocatechin-3-gallate, a specific type of polyphenol found most abundantly in green tea. Chemically, it belongs to a group called catechins — plant-made molecules that often act like mild protective chemicals for the plant and, when we consume them, can interact with our bodies in interesting ways. If you drink green tea or matcha, EGCG is one of the main active ingredients you’re getting.

At a practical level, EGCG is known for two broad properties: it can act as an antioxidant and it can influence cellular signalling. As an antioxidant, EGCG can neutralize some reactive molecules that damage cells (often called free radicals). But more importantly, it also turns on the body’s own protective systems — for example, cellular pathways that boost the production of enzymes that clean up oxidative stress. Beyond that, EGCG can change how cells talk to each other by modifying signalling pathways that control inflammation, growth, and survival. In plain terms, it can damp down excessive inflammatory signals in some situations and can slow down abnormal cell growth in others.

A lot of the excitement around EGCG comes from laboratory and animal studies showing it affects processes linked to heart health, brain health, metabolism, and cancer. In cells and animals, EGCG has been shown to reduce inflammation, protect nerve cells, improve blood vessel function, and interfere with pathways that cancer cells use to grow. However, what happens in a test tube or a mouse does not always happen the same way in people. When humans drink green tea, EGCG is partially broken down in the gut and liver into other compounds, and the amounts that reach different tissues are smaller and more complex than the pure compound used in lab experiments. That’s why clinical evidence in people is more mixed and why researchers are careful about making strong health claims.

How you consume EGCG matters. Drinking green tea delivers EGCG together with water, caffeine, and other tea compounds, and this is generally considered safe for most people. Concentrated supplements deliver much higher doses of EGCG than a few cups of tea and have been linked, in rare cases, to liver problems. EGCG can also interfere with the absorption of non-heme iron (the kind found in plants) and can interact with certain medications. Because of this, supplements should be used cautiously and ideally under medical advice.

Another important point is that EGCG doesn’t act alone. The gut microbes in your intestines transform EGCG into other molecules, and those transformations can influence what effects occur in your body. So the final biological activity you get from green tea depends not only on the EGCG amount but also on how your body and your microbiome process it.

In short, EGCG is a biologically active compound in green tea with antioxidant and cell-signalling effects that may support aspects of health. Most evidence supports drinking green tea as a safe way to get modest amounts of EGCG; high-dose supplements are more uncertain and carry more risk. If you’re considering concentrated EGCG products for health reasons, it’s wise to talk with a healthcare professional first.

(Source : ChatGPT) (Image : FreePik)

Polyphenols are a large family of compounds found in plants — things like tea, berries, apples, onions, wine, and many herbs and spices. When people say polyphenols have “immunomodulatory” effects, they mean these compounds can change how the immune system behaves. Importantly, they don’t act like a single on/off switch. Instead they act more like a dimmer or a thermostat: in some situations they dial down excessive inflammation, and in other situations they can support immune defences that are too weak. Below I’ll explain, in plain language, the main ways scientists think polyphenols achieve those effects.

One of the simplest ways polyphenols influence immunity is through their effect on oxidative stress. Immune cells produce reactive oxygen species (ROS) as part of the attack on microbes, but too much ROS can damage tissues and keep inflammation going. Many polyphenols are antioxidants — they neutralize some ROS directly and also turn on the body’s own antioxidant defenses (for example by activating the Nrf2 pathway). By lowering oxidant damage, polyphenols help prevent an inflammatory cycle that would otherwise perpetuate tissue injury and overactive immune responses.

Another major route is by changing immune signalling inside cells. Immune responses are controlled by networks of proteins and chemical signals — transcription factors like NF-κB and signaling pathways such as MAP kinases. These pathways tell immune cells to release inflammatory molecules called cytokines (examples you may have heard: TNF-α, IL-6, IL-1β). Many polyphenols interfere with those intracellular signals so that the production of pro-inflammatory cytokines is reduced. At the same time, some polyphenols can enhance anti-inflammatory signals (for example increasing IL-10 or supporting regulatory T cells). The net result is a shift in the balance away from excessive inflammation toward a more controlled response.

Polyphenols also act on specific kinds of immune cells. They can affect macrophages (the “big eater” cells that clean up debris and secrete signals), dendritic cells (which present bits of invaders to T cells), and different types of T cells (which coordinate adaptive immunity). For instance, polyphenols can make macrophages less likely to adopt a highly inflammatory state, and they can influence whether T cells become the aggressive, inflammation-driving types (Th1 or Th17) or the regulatory types (Tregs) that calm things down. By nudging these cell decisions, polyphenols shape how strong and what kind of immune response develops.

The gut is another important place where polyphenols influence immunity. Many polyphenols aren’t absorbed unchanged — they are altered by the microbes in the gut into smaller molecules, and those metabolites can have biological activity. Polyphenols also change the composition and behavior of the gut microbiota itself. Because a large portion of the immune system sits in or near the gut (the gut-associated lymphoid tissue), changes in microbiota and in microbial metabolites translate into changes in systemic immune tone and local gut immunity. In short, polyphenols can act indirectly through microbiome shifts as well as directly on immune cells.

There are other mechanisms worth noting. Polyphenols can block or reduce activation of inflammasomes — protein complexes that trigger a particular type of inflammatory response — and they can interfere with pattern-recognition receptors such as Toll-like receptors (TLRs), which are the immune system’s early-warning detectors for invaders. Some polyphenols can also alter gene expression by epigenetic means (changing how tightly certain genes are turned on or off), which can produce longer-lasting effects on immune behavior.

It’s important to keep perspective about what this science means in the real world. Much of the detailed mechanistic work comes from cell culture or animal studies where concentrations of polyphenols and direct exposures are very different from what happens when you eat a blueberry or drink tea. In humans, polyphenols are extensively metabolized, and only small amounts of parent compounds reach the bloodstream; often the metabolites — or the changes caused in the microbiome — are the active players. Clinical evidence that eating polyphenol-rich foods reduces disease risk or meaningfully treats immune disorders exists in some cases, but it’s variable and context-dependent. Also, because polyphenols can both raise and lower different parts of the immune response, they are not universally “immune-boosting” in a simple sense — their effect depends on the existing state of the immune system.

To sum up: polyphenols modulate immunity through antioxidant effects, by altering intracellular signalling and cytokine production, by influencing immune cell types and their decisions, by shaping gut microbiota and their metabolites, and through other routes like inflammasome inhibition and epigenetic changes. They tend to promote balance — limiting unnecessary or damaging inflammation while preserving or supporting appropriate defensive responses — but the details depend on the specific polyphenol, its metabolites, dose, and the person’s biology. If you’re interested in practical takeaways, a diet with a variety of polyphenol-rich plant foods is a reasonable, low-risk way to support overall health, but it’s not a substitute for medical treatment when the immune system is actively malfunctioning.

(Source : ChatGPT)

There is suggestive evidence that oolong tea can help some inflammatory skin problems—most convincingly for atopic dermatitis (eczema)—but the data are limited, and for psoriasis the evidence is largely preclinical or anecdotal rather than proven in clinical trials.

Longer, medical-style explanation:

Oolong tea is derived from Camellia sinensis and contains a mix of tea polyphenols (catechins and their oxidation products), modest amounts of caffeine, and a range of other bioactive molecules. Those polyphenols have antioxidant, anti-inflammatory and “antiallergic” actions in laboratory studies: they can reduce proinflammatory cytokine signaling, stabilize or reduce mast-cell activation, and scavenge reactive oxygen species — mechanisms that are plausibly relevant to inflammatory skin diseases such as atopic dermatitis. Reviews of tea polyphenols and focused papers on the catechin EGCG summarize these pathways and the experimental evidence supporting them. (PMC)

Clinical human data for oolong and eczema are modest but noteworthy. A controlled clinical series conducted in Japan reported improvement in a substantial fraction of patients with treatment-resistant atopic dermatitis who drank oolong tea daily; roughly two-thirds showed marked or moderate improvement after one month and more than half maintained a response at six months in that observational/clinical series. The protocol, as used in published descriptions and integrative dermatology summaries, involved steeping a defined amount of dried oolong leaves and drinking the infusion divided through the day. These results are encouraging but must be read in context: the study was relatively small, not a large double-blind randomized controlled trial, and confounding (diet, concurrent treatments, placebo effects) cannot be fully excluded. (PubMed)

Laboratory and animal research strengthens biological plausibility. Recent preclinical work comparing tea extracts shows that oolong and other tea extracts can reduce scratching, epidermal hyperplasia, mast cell counts and key inflammatory mediators in mouse models of allergic dermatitis. Separate mechanistic studies find that both systemic and topical administration of tea catechins (especially EGCG) reduce acute and chronic itch and downregulate inflammatory signaling in keratinocytes and immune cells — findings that help explain the clinical signals seen in some human reports. (MDPI)

When it comes to psoriasis the picture is different. Psoriasis is a Th17-driven, hyperproliferative disorder of epidermis and immune signaling; laboratory and animal studies show that EGCG and other polyphenols can attenuate psoriasiform inflammation in mouse models and modulate pathways (STAT3, NF-κB, IL-17 axis) relevant to psoriasis. However, high-quality clinical trial evidence of benefit for oral oolong tea in people with psoriasis is essentially lacking, and available human reports tend to be anecdotal or extrapolated from green tea/EGCG work or small topical formulation studies. Thus, while the molecular data and animal models support the possibility that tea polyphenols could help, clinical proof for oolong in psoriasis is currently insufficient. (SpringerLink)

Practical clinical considerations and safety: if patients wish to try oolong as an adjunctive, a few practical points are important. Moderate consumption (a few cups daily) is generally well tolerated for most adults, but oolong contains caffeine and can interfere with sleep or exacerbate anxiety in sensitive individuals; tea also reduces non-heme iron absorption if taken with iron-rich meals and can contribute fluoride exposure if consumed in very large amounts. Patients with significant or progressive dermatitis or psoriasis should not stop standard prescribed therapies in favour of tea alone; instead oolong can be considered as a complementary measure and patients should discuss it with their dermatologist. Finally, topical preparations containing stabilized tea catechins are an active area of research and may offer different risk/benefit profiles compared with simply drinking tea. (PMC)

Bottom line: the best clinical signal for oolong tea is in atopic dermatitis, where limited human data plus supportive preclinical studies indicate a possible benefit; for psoriasis the evidence is mainly preclinical and anecdotal at present. The biological plausibility is strong because tea polyphenols are anti-inflammatory and immunomodulatory, but higher-quality randomized clinical trials and standardized dosing studies are still needed before oolong can be recommended as a proven treatment. (PubMed)

(...) Green tea has stronger and more consistent evidence (especially due to EGCG) for anti-inflammatory and topical benefits in skin conditions; oolong shows promise—notably for atopic dermatitis—but the clinical data are smaller and less robust.

(Source : ChatGPT) (Image : Qwen)